AXSM news

Axsome reported Q3 revenue growth of 52% driven by Auvelity and Sunosi, surpassing a billion dollar annual run rate.

Axmore reported Q2 2026 financial results with AUVELITY and SUNOSI driving growth, alongside clinical advances in its neuroscience pipeline.

Axsome Therapeutics announced the FDA accepted its NDA for AXS-12 to treat cataplexy in narcolepsy, setting a PDUFA target date of May 1, 2027. This regulatory milestone advances the biopharmaceutical company's CNS pipeline and creates a path to market.

Axsome Therapeutics adopted an Executive Severance and Change in Control Plan effective June 5, 2026, to provide severance benefits to key employees upon involuntary termination. The plan supersedes prior severance arrangements and is intended to retain executive talent during organizational transit…

Axsome Therapeutics resolved all patent litigation related to SUNOSI (solriamfetol) by settling with the remaining first-to-file generic applicant, allowing five companies to sell generic versions starting September 1, 2040 (or March 1, 2040 if no pediatric exclusivity). The settlement extends marke…